By Colin Kellaher

 

ImmunoGen Inc. on Monday said the U.S. Food and Drug Administration granted priority review to its application for mirvetuximab soravtansine monotherapy in certain patients with ovarian cancer.

The Waltham, Mass., biotechnology company is seeking approval of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have previously received one to three systemic treatments.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. ImmunoGen said the agency set a target action date of Nov. 28 for the application.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

May 23, 2022 06:54 ET (10:54 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more ImmunoGen Charts.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more ImmunoGen Charts.